Renal impairment and anemia during triple therapy

We read with great interest the recently published review by Romero-Gòmez and colleagues concerning the management of anemia induced by triple therapy in patients with chronic hepatitis C [1]. In their work, authors thoroughly discuss about pathophysiological mechanisms responsible for the anemia observed during triple therapy with telaprevir or boceprevir, remark baseline and on-treatment factors predictive of more severe anemization, and propose a sequential strategy to manage anemia based first on ribavirin dose reduction and then on epoetin administration.